Latest Breaking News On - Rivoceranib apatinib - Page 1 : comparemela.com

Camrelizumab in Combination with Rivoceranib (Apatinib) Significantly Prolonged Overall Survival and Progression-Free Survival vs. Sorafenib in Patients with Unresectable Hepatocellular Carcinoma in a Multinational Phase 3 Trial, a Joint Program with Elevar Therapeutics

France generalSouth koreaRepublic of koreaRivoceranib apatinibHengrui pharmaElevar therapeutics incCrystalgenomics incJiangsu hengrui pharmaceuticals co ltdJiangsu hengrui pharmaceuticals coI jiangsu hengrui pharmaceuticals co ltdEuropean society for medical oncologySignificantly prolonged overall survivalProgression free survivalUnresectable hepatocellular carcinomaMultinational phaseJoint program